Objective To investigate the clinical outcomes and toxicity in patients
with locally advanced cervical cancer treated with supplementary
applicator guided-intensity modulated radiation therapy (IMRT) based on
conventional intracavitary brachytherapy (IC/IMRT). Population Large
high risk clinical target volume (HR-CTV) volume (>40cc) at
the time of brachytherapy cervical cancer patients were recruited.
Methods This study is a retrospective analysis of 76 patients with
locally advanced cervical cancer (FIGO IIB-IVA) treated with concurrent
chemo-radiotherapy followed by IC/IMRT between June 2010 and October
2016. External radiotherapy (45 Gy in 25 fractions) with cisplatin
chemotherapy treated before IC/IMRT. The prescription dose for HR-CTV
and IR-CTV were 6 Gy and 5 Gy per fraction for 5 fractions respectively.
Results: Mean HR-CTV was 65.8±23.6 cc at the time of brachytherapy. D90
for HR-CTV and IR-CTV were 88.7±3.6 Gy and 78.1±2.5 Gy. D2cc for
bladder, rectum, sigmoid and small intestine were 71.8±3.8 Gy, 64.6±4.9
Gy, 63.9±5.3 Gy and 56.7±8.7 Gy respectively. Median follow-up was 85
months (47.9-124.2 months). Five-year local recurrence free survival
rate, metastasis recurrence free survival rate, disease free survival
rate and cancer special survival rate were 87.6%, 82.4%, 70.9% and
76.3%, respectively. The grade 1+2 gastrointestinal and urinary late
toxicities were 15.8% and 21.1%, while grade 3 late toxicities were
3.9% and 5.2%, respectively. Neither acute nor late grade 4
gastrointestinal or urinary toxicities were seen. Conclusions: The
combination of ICBT with an applicator-guided supplementary IMRT boost
achieved an excellent local control and overall survival with low
toxicity for bulky residual cervical tumor
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.